Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT1 | P17948 | 1/20 | 0.39 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.39 |
| ▸ | MINK1 | Q8N4C8 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 3/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | NPC1 | O15118 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.37 |
| ▸ | MAPK14 | Q16539 | 4/20 | 0.36 |
| ▸ | PIM1 | P11309 | 3/20 | 0.36 |
| ▸ | PIM2 | Q9P1W9 | 3/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.34 |
| ▸ | S100A4 | P26447 | 2/20 | 0.33 |
| ▸ | CDC25A | P30304 | 2/20 | 0.33 |
| ▸ | CDC25B | P30305 | 2/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | APAF1 | O14727 | 1/20 | 0.33 |
| ▸ | MAP2K7 | O14733 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10364834 | 0.88 | PDE5A (0.39) | FLT1MAPK11MINK1RAB9AALDH1A1 | |
| SCHEMBL24332597 | 0.86 | FLT1 (0.43) | FLT1MAPK11MINK1RAB9AALDH1A1 | |
| SCHEMBL14990751 | 0.85 | MAPK14 (0.40) | FLT1MAPK11MINK1MAPK14KDM4E | |
| SCHEMBL15086681 | 0.84 | PIM1 (0.36) | FLT1MAPK11MINK1RAB9AALDH1A1 | |
| SCHEMBL4073505 | 0.80 | MAPK14 (0.41) | RAB9AALDH1A1NPC1SMN1; SMN2RXFP1 | |
| SCHEMBL981551 | 0.80 | PIM1 (0.36) | FLT1MAPK11MINK1RAB9AALDH1A1 | |
| SCHEMBL4071394 | 0.75 | PDE5A (0.40) | MAPK14PIM1PIM2CYP2D6MET | |
| SCHEMBL4079295 | 0.74 | MAPK14 (0.44) | FLT1RAB9ANPC1SMN1; SMN2MAPK14 | |
| SCHEMBL4072097 | 0.73 | HSD11B1 (0.49) | RAB9AALDH1A1NPC1SMN1; SMN2MAPK14 | |
| SCHEMBL4076128 | 0.73 | MAPK14 (0.44) | MAPK14PIM1PIM2KDM4ENPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2303267-B1 | POLYMORPHIC FORM OF A [1, 2, 4] TRIAZOLO [4, 3-A]PYRIDINE DERIVATIVE FOR TREATING INFLAMMATORY DISEASES | PFIZER LTD (GB) | 2013-07-03 | — | — | EP | disclosed |
| EP-2303267-B1 | POLYMORPHIC FORM OF A [1, 2, 4] TRIAZOLO [4, 3-A]PYRIDINE DERIVATIVE FOR TREATING INFLAMMATORY DISEASES | PFIZER LTD (GB) | 2013-07-03 | — | — | EP | disclosed |
| US-8222273-B2 | Polymorphic form of a [1,2,4]triazole[4,3-A] pyridine derivative inflammatory diseases | PFIZER LIMITED (GB) | 2012-07-17 | — | — | US | disclosed |
| US-8222273-B2 | Polymorphic form of a [1,2,4]triazole[4,3-A] pyridine derivative inflammatory diseases | PFIZER LIMITED (GB) | 2012-07-17 | — | — | US | disclosed |
| US-8222273-B2 | Polymorphic form of a [1,2,4]triazole[4,3-A] pyridine derivative inflammatory diseases | PFIZER LIMITED (GB) | 2012-07-17 | — | — | US | disclosed |
| US-20110003848-A1 | Polymorphic Form Of A [1,2,4]Triazole[4,3-A] Pyridine Derivative For Treating Inflammatory Diseases | PFIZER LIMITED (GB) | 2011-01-06 | — | — | US | disclosed |
| US-20110003848-A1 | Polymorphic Form Of A [1,2,4]Triazole[4,3-A] Pyridine Derivative For Treating Inflammatory Diseases | PFIZER LIMITED (GB) | 2011-01-06 | — | — | US | disclosed |
| US-20110003848-A1 | Polymorphic Form Of A [1,2,4]Triazole[4,3-A] Pyridine Derivative For Treating Inflammatory Diseases | PFIZER LIMITED (GB) | 2011-01-06 | — | — | US | disclosed |
| WO-2009098612-A2 | POLYMORPHIC FORM OF A [1, 2, 4] TRIAZOLO [4, 3-A] PYRIDINE DERIVATIVE FOR TREATING INFLAMMATORY DISEASES | PFIZER LIMITED (GB) | 2009-08-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110003848-A1 | Polymorphic Form Of A [1,2,4]Triazole[4,3-A] Pyridine Derivative For Treating Inflammatory Diseases | CYP1B1, UBE2V1, CYP4B1 | FLT1 1543/4885MAPK11 2887/4885MINK1 2168/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.